The company’s CEO confirmed the news yesterday.
Boston Scientific (NYSE:BSX) CEO Mike Mahoney yesterday confirmed that the company’s entry into the transcatheter aortic valve market, Lotus, will remain off the market for the rest of the year.
Last November news of another Lotus delay pared $3 billion from Boston’s market capitalization. The Marlborough, Mass.-based company, which recalled the Lotus transcatheter aortic heart valve in February 2017 over issues with its locking mechanism, said it no longer expected the ensuing manufacturing and design specification changes to get the valve back on the market in Europe or allow the final filing in its pre-market approval bid with the FDA by January 2018.
